Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda's Rozerem Substance Abuse/Toxicity Claims Draw FDA Rebuke

This article was originally published in PharmAsia News

Executive Summary

Takeda misrepresents its sleep aid Rozerem (ramelteon) in sales materials aimed at physicians who treat substance abusers by claiming the product has "no likelihood of abuse and no detectable toxicity," FDA's Division of Drug Marketing, Advertising and Communications charges

You may also be interested in...



Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success

Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success

Somaxon's Silenor Gains An FDA Approval, But Can The Pharma Afford A Launch?

Somaxon hopes to launch its insomnia drug in the second half of 2010, but is still searching for a U.S. commercial partner.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel